Vandria is at the forefront of developing innovative mitochondrial therapeutics, specifically focusing on mitophagy inducers that aim to rejuvenate cells and enhance mitochondrial health. Mitochondria are essential organelles responsible for energy production in cells, and their proper function is crucial for overall cellular health. Vandria's approach involves the selective removal of damaged mitochondria through a process known as mitophagy, which not only eliminates dysfunctional components but also stimulates the creation of new, healthy mitochondria. This rejuvenation process is particularly significant in addressing age-related and chronic diseases, as the decline in mitochondrial function is linked to various health conditions, including mild cognitive impairment and neurodegenerative disorders.

The company has developed a proprietary in vitro screening platform that has led to a pipeline of next-generation small molecule mitophagy inducers. These compounds are specifically designed to optimize pharmacokinetic properties, allowing them to target various tissues and address specific unmet medical needs. Vandria's research pipeline includes programs aimed at conditions such as sporadic inclusion body myositis, non-alcoholic steatohepatitis (NASH), and idiopathic pulmonary fibrosis (IPF), among others. By focusing on enhancing mitochondrial function through targeted therapies, Vandria aims to improve the quality of life for individuals affected by these debilitating conditions.

Switzerland

Vandria is a biopharmaceutical company at the vanguard of mitochondrial research. They develop best-in-class small molecule mitophagy inducers to treat age-related and chronic diseases. Vandria is also developing mitophagy-inducing small molecules to address muscle, lung, and liver diseases, as well as a separate program targeting ferroptosis, a form of cell death.

Vandria

Company Details